Company profile
Numab Therapeutics AG
Numab is a Swiss biotech company that innovates and develops antibody-based therapeutics. A particular focus is given to the discovery of protein therapeutics against non-traditional antibody targets, such as complex membrane proteins. Numab’s proprietary discovery technology is particularly well suited to approach this class of drug-targets that formerly was inaccessible to most protein-binder platforms.
Source: startup.ch
Highlights
Top 100 Swiss Startup Award 2021
Top 100 Swiss Startup Award 2014
Innosuisse Certificate
Top 100 Swiss Startup Award 2013
More news about Numab Therapeutics AG
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
